Bristol-Myers Squibb
BMY
$67.68
Share price
1.05%
Change (1 day)
-6.53%
Change (1 year)
Categories
P/S ratio for Bristol-Myers Squibb (BMY)
P/S ratio as of March 2023 (TTM): 3.08
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.07731. At the end of 2022 the company had a P/S ratio of 3.31.
P/S ratio history for Bristol-Myers Squibb from 2001 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 3.31 | 11.08% |
| 2021 | 2.98 | -9.5% |
| 2020 | 3.30 | -39.73% |
| 2019 | 5.47 | 46.19% |
| 2018 | 3.74 | -22.49% |
| 2017 | 4.83 | -3.97% |
| 2016 | 5.03 | -27.14% |
| 2015 | 6.90 | 12.28% |
| 2014 | 6.15 | 15.44% |
| 2013 | 5.32 | 76.57% |
| 2012 | 3.01 | 7.25% |
| 2011 | 2.81 | 21.74% |
| 2010 | 2.31 | 0.64% |
| 2009 | 2.29 | 4.12% |
| 2008 | 2.20 | -18.56% |
| 2007 | 2.71 | -6.14% |
| 2006 | 2.88 | 23.12% |
| 2005 | 2.34 | -9.03% |
| 2004 | 2.57 | -3.07% |
| 2003 | 2.66 | 2.56% |
| 2002 | 2.59 | -49.74% |
| 2001 | 5.15 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.02 | 63.00% | 🇺🇸 USA |
 Novartis NVS | 3.43 | 11.34% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.27 | -26.15% | 🇺🇸 USA |
 AbbVie ABBV | 4.80 | 56.07% | 🇺🇸 USA |
 Eli Lilly LLY | 11.2 | 264.35% | 🇺🇸 USA |
 Amgen AMGN | 4.83 | 56.91% | 🇺🇸 USA |
 Sanofi SNY | 2.76 | -10.35% | 🇫🇷 France |
 Biogen BIIB | 3.83 | 24.45% | 🇺🇸 USA |
 Merck MRK | 4.49 | 45.87% | 🇺🇸 USA |
 AstraZeneca AZN | 4.75 | 54.24% | 🇬🇧 UK |